Topic: Breastcancer.org Podcasts: Listen to Experts Discuss

Forum: Community/Mod Announcements & Breastcancer.org News — Moderator-generated forum to present our announcements or requests and organization and website news. Please do not post here if you are not a Moderator. Thank you!

Posted on: Dec 12, 2013 07:28AM - edited Oct 5, 2014 11:45AM by moderators

Posted on: Dec 12, 2013 07:28AM - edited Oct 5, 2014 11:45AM by moderators

moderators wrote:

Please go here to read about and listen to all our Podcasts! We will also be posting podcasts below as they air.

Note: Podcasts will be available in transcript form about 24 - 48 hours after the Podcasts have aired.

To send a PM to the Mods: community.breastcancer.org/my/...

Page 26 of 26 (257 results)

Dec 16, 2022 07:03AM moderators wrote:

Experimental Elacestrant Seems Effective for Breast Cancer Resistant to Other Types of Hormonal Therapy
Dec 8, 2022

Dr. Virginia Kaklamani explains the latest results from the EMERALD trial comparing elacestrant to the standard of care.

Doctors are looking for new treatment options for people diagnosed with metastatic hormone receptor-positive, HER2-negative breast cancer that has grown during treatment with hormonal therapy and a CDK4/6 inhibitor. Dr. Virginia Kaklamani is part of the team investigating elacestrant, an oral medicine, to see if offers more benefits than Faslodex (chemical name: fulvestrant), which is the current standard of care.

Listen to the podcast to hear Dr. Kaklamani explain:

  • the type of medicine elacestrant is and how it works
  • why it's important that elacestrant showed benefits for breast cancers with an ESR1 mutation
  • when we might hear if elacestrant is approved by the U.S. Food and Drug Administration (FDA)
Listen now or read the transcript.
To send a PM to the Mods: community.breastcancer.org/my/...

Dec 16, 2022 07:04AM moderators wrote:

Enhertu Offers Better Overall Survival Than Kadcyla for Metastatic HER2-Positive Breast Cancer
Dec 9, 2022

Dr. Sara Hurvitz discusses new overall survival results from the DESTINY-Breast03 study.

2021 results from the DESTINY-Breast03 study showed that Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki) more than doubled the 12-month progression-free survival rate compared to Kadcyla (chemical name: T-DM1 or ado-trastuzumab emtansine) in people diagnosed with metastatic HER2-positive breast cancer that had been previously treated.

At the 2022 San Antonio Breast Cancer Symposium, Dr. Sara Hurvitz presented new overall survival results, showing that Enhertu also improves overall survival compared to Kadcyla.

Listen to the episode to hear Dr. Hurvitz explain:

  • overall survival and progression-free survival results
  • severe side effects of Enhertu
  • how the researchers managed any severe lung problems that developed in people receiving Enhertu

Listen now or read the transcript.

To send a PM to the Mods: community.breastcancer.org/my/...

Dec 16, 2022 07:04AM moderators wrote:

What I Get From Breastcancer.org Meetups
Dec 10, 2022

Breastcancer.org Community Member Vanessa Onsurez talks about her diagnosis, #ThisIsMBC, and Meetups.

Vanessa Onsurez, who was diagnosed with metastatic breast cancer in 2021, explains the #ThisIsMBC project at the 2022 San Antonio Breast Cancer Symposium and the benefits she gets from the Breastcancer.org Virtual Community Meetups.

Listen to the episode to hear Vanessa discuss:

  • how she got involved in #ThisIsMBC
  • how she found Breastcancer.org and what she's learned in the Meetups
  • what she wants to leave as her legacy
Listen now or read the transcript.
To send a PM to the Mods: community.breastcancer.org/my/...

Dec 16, 2022 07:04AM moderators wrote:

2022 SABCS Key Take-Aways
Dec 13, 2022

Dr. Stephanie Graff explains the most interesting research presented at the 2022 San Antonio Breast Cancer Symposium.

The 2022 San Antonio Breast Cancer Symposium featured five days of research presentations, educational sessions, and posters. The amount of research presented can be overwhelming, so we asked Dr. Stephanie Graff to break down the key take-aways for people who've been diagnosed with breast cancer.

Listen to the episode to hear Dr. Graff explain:

  • updated results from the monarchE study
  • updated results from the TAILORx study
  • results from the RIGHT Choice trial
  • her thoughts on whether HER2-low breast cancer is a distinct subtype

Listen now or read the transcript.

To send a PM to the Mods: community.breastcancer.org/my/...

Dec 16, 2022 07:04AM moderators wrote:

GRASP: Helping Advocates Understand Research, Helping Researchers Understand Patients
Dec 14, 2022

Patient advocates and researchers who are part of GRASP talk about what they've learned from the program.

GRASP – Guiding Researchers and Advocates to Scientific Partnership – connects patients, doctors, and researchers to exchange ideas and learn from each other. At the 2022 San Antonio Breast Cancer Symposium, we asked advocates and researchers who are part of the program what they have learned from the program.

Listen to the episode to learn about:

  • plans for launching a Spanish version of the program
  • how the mentor aspect of the program works
  • how the program helps researchers refine their programs

Listen now or read the transcript.

To send a PM to the Mods: community.breastcancer.org/my/...

Dec 16, 2022 07:05AM moderators wrote:

Experimental Capivasertib Seems Promising for Advanced-Stage, Hormone Receptor-Positive, HER2-Negative Breast Cancer
Dec 15, 2022

Dr. Nicholas Turner explains research looking at capivasertib, a new targeted therapy medicine.

Researchers are always looking for new treatments for advanced-stage breast cancer. Dr. Nicholas Turner explains the results of the CAPitello-291 trial, looking capivasertib, an experimental targeted therapy medicine, in combination with Faslodex (chemical name: fulvestrant) as a treatment for advanced-stage, hormone receptor-positive, HER2-negative breast cancer that has become resistant to the aromatase inhibitors.

Listen to the episode to hear Dr. Turner explain:

  • how capivasertib works
  • the results of the CAPitello-291 trial
  • how capivasertib worked on cancers previously treated with a CDK4/6 inhibitor
Listen now or read the transcript.
To send a PM to the Mods: community.breastcancer.org/my/...

Jan 11, 2023 10:22AM moderators wrote:

Hi all,

Because there is a duplicate thread for these Podcasts, we're locking this thread and only posting new Podcasts on the other thread from now on. If you've saved this thread as a Favorite to follow new Podcasts, please instead save the other thread as a Favorite so you won't miss new episodes. Here is a link to the other thread: https://community.breastcancer.org/forum/73/topics...

Thank you for your understanding and your support of our Podcast program!

--The Mods

To send a PM to the Mods: community.breastcancer.org/my/...

Page 26 of 26 (257 results)

Scroll to top button